Emotra is a small start-up company in Sweden that is part of the AstraZeneca BioVentureHub. We have developed a psychophysiological CE-marked product called EDOR to identify an at-risk group among depressed patients called hyporeactive. Data suggests that hyporeactive patients are more vulnerable to relapses into depression, which is the focus for the company. Depression with 264 million affected per year is a major health challenge and market.